These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37740667)

  • 1. Comparative efficacy of quetiapine by dose and formulation for psychosis in schizophrenia: A systematic review and dose-response model-based network meta-analysis.
    Terao I; Yokoi A; Fukushima H
    J Psychopharmacol; 2023 Oct; 37(10):953-959. PubMed ID: 37740667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
    Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
    Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.
    Srisurapanont M; Likhitsathian S; Suttajit S; Maneeton N; Maneeton B; Oon-Arom A; Suradom C
    Drug Alcohol Depend; 2021 Feb; 219():108467. PubMed ID: 33385693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quetiapine immediate release v. placebo for schizophrenia: systematic review, meta-analysis and reappraisal.
    Hutton P; Taylor PJ; Mulligan L; Tully S; Moncrieff J
    Br J Psychiatry; 2015 May; 206(5):360-70. PubMed ID: 25934300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study.
    Kahn RS; Schulz SC; Palazov VD; Reyes EB; Brecher M; Svensson O; Andersson HM; Meulien D;
    J Clin Psychiatry; 2007 Jun; 68(6):832-42. PubMed ID: 17592906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies.
    Meulien D; Huizar K; Brecher M
    Hum Psychopharmacol; 2010 Mar; 25(2):103-15. PubMed ID: 20196185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.
    Yunusa I; Rashid N; Demos GN; Mahadik BS; Abler VC; Rajagopalan K
    Adv Ther; 2022 May; 39(5):1993-2008. PubMed ID: 35247186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of quetiapine immediate- and extended-release formulations for bipolar depression: A systematic review and network meta-analysis of double-blind, randomized placebo-controlled trials.
    Kishi T; Ikuta T; Sakuma K; Matsuda Y; Iwata N
    J Psychiatr Res; 2019 Aug; 115():121-128. PubMed ID: 31128502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned.
    Cutler AJ; Tran-Johnson T; Kalali A; Aström M; Brecher M; Meulien D
    Psychopharmacol Bull; 2010; 43(4):37-69. PubMed ID: 21240151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER.
    Knapp M; Locklear J; Järbrink K
    Curr Med Res Opin; 2009 Jul; 25(7):1593-603. PubMed ID: 19469696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study.
    Mamo DC; Uchida H; Vitcu I; Barsoum P; Gendron A; Goldstein J; Kapur S
    J Clin Psychiatry; 2008 Jan; 69(1):81-6. PubMed ID: 18312041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial.
    Jensen KG; Correll CU; Rudå D; Klauber DG; Decara MS; Fagerlund B; Jepsen JRM; Eriksson F; Fink-Jensen A; Pagsberg AK
    J Am Acad Child Adolesc Psychiatry; 2019 Nov; 58(11):1062-1078. PubMed ID: 30858012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance, sedation and patient satisfaction in patients with schizophrenia: a randomised, double-blind, crossover study (eXtRa).
    Riedel M; Schmitz M; Østergaard PK; Ferrannini L; Franco MA; Alfano V; Vansvik ED
    Schizophr Res; 2015 Mar; 162(1-3):162-8. PubMed ID: 25592805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial.
    Jensen KG; Gärtner S; Correll CU; Rudå D; Klauber DG; Stentebjerg-Olesen M; Fagerlund B; Jepsen JR; Fink-Jensen A; Juul K; Pagsberg AK
    Psychopharmacology (Berl); 2018 Mar; 235(3):681-693. PubMed ID: 29185022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
    Leucht S; Crippa A; Siafis S; Patel MX; Orsini N; Davis JM
    Am J Psychiatry; 2020 Apr; 177(4):342-353. PubMed ID: 31838873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of clinical usage of quetiapine XR and quetiapine IR in outpatients with schizophrenia in Denmark.
    Emborg C; Hallerbäck T; Jörgensen L; Carlborg A
    Hum Psychopharmacol; 2012 Sep; 27(5):492-8. PubMed ID: 22996616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis.
    Pagsberg AK; Tarp S; Glintborg D; Stenstrøm AD; Fink-Jensen A; Correll CU; Christensen R
    J Am Acad Child Adolesc Psychiatry; 2017 Mar; 56(3):191-202. PubMed ID: 28219485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects.
    Nord M; Nyberg S; Brogren J; Jucaite A; Halldin C; Farde L
    Int J Neuropsychopharmacol; 2011 Nov; 14(10):1357-66. PubMed ID: 21477416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.
    Lindenmayer JP; Brown D; Liu S; Brecher M; Meulien D
    Psychopharmacol Bull; 2008; 41(3):11-35. PubMed ID: 18779774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.